Drug Profile
SAB 185
Alternative Names: Anti-SARS-CoV-2 human immunoglobulin intravenous (Tc bovine-derived) - SAB Biotherapeutics; SAB-185Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator SAB Biotherapeutics
- Developer National Institute of Allergy and Infectious Diseases; SAB Biotherapeutics
- Class Antivirals; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (IV)
- 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (IV) (NCT04518410)
- 26 Apr 2023 Efficacy and adverse events data from a phase III ACTIV-2 trial in COVID-2019 infections released by SAB Biotherapeutics